OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Living with cancer·Standard of care

Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei: the decisions you may face

Cancer page →Second-opinion finder →

4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

LAMN confined to the appendix

One path named

Appendicectomy with clear margin; no right hemicolectomy; surveillance imaging if mucin was found outside the appendix.

Guideline
NCCN Guidelines: Colon Cancer (appendiceal section)
The path, in plain words
CT (computed tomography)Standard of care

A CT scan is a fast 3D X-ray that shows the size and shape of tumours and whether they have spread.

  • Fast, ubiquitous
  • Sub-millimetre resolution
  • Standard for RECIST response
Also referenced:Colectomy
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
CT (computed tomography)
  • Anatomic only; cannot distinguish scar from live tumour
  • Radiation dose
  • Poor for brain, marrow, and small peritoneal disease
Questions to ask about this decision
  1. Is CT (computed tomography) the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Colon Cancer (appendiceal section)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (lamn confined to the appendix), which of the standard options do you recommend and why?
    Why: Guideline options include: Appendicectomy with clear margin; no right hemicolectomy; surveillance imaging if mucin was found outside the appendix.

Add these to your appointment list, or take the full question set for this cancer.

Early / localised

Pseudomyxoma peritonei, resectable

2 options

Complete cytoreductive surgery (peritonectomy and organ resection) with hyperthermic intraperitoneal chemotherapy, mitomycin or oxaliplatin, in a specialist centre.

Guideline
NCCN Guidelines: Colon Cancer (appendiceal section)
The options, in plain words
HIPEC / PIPAC (intraperitoneal chemotherapy)Established

Washing the abdominal cavity with heated chemotherapy during surgery to kill microscopic peritoneal deposits.

  • High local concentration
Mitomycin CApprovedAlkylating antibiotic (bioreductive)

The chemotherapy given with radiation to cure anal cancer without surgery, used as a bladder instillation after tumour resection, and since 2020-25 in gel form for upper-tract and recurrent bladder cancers.

Also referenced:HIPEC (hyperthermic intraperitoneal chemotherapy)Peritoneal metastasisDebulking (cytoreductive surgery)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
HIPEC / PIPAC (intraperitoneal chemotherapy)
  • Morbidity, centre expertise
  • Mixed trial results
Questions to ask about this decision
  1. Between HIPEC / PIPAC (intraperitoneal chemotherapy) and Mitomycin C, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Colon Cancer (appendiceal section)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (pseudomyxoma peritonei, resectable), which of the standard options do you recommend and why?
    Why: Guideline options include: Complete cytoreductive surgery (peritonectomy and organ resection) with hyperthermic intraperitoneal chemotherapy, mitomycin or oxaliplatin, in a specialist centre.
  6. Am I a candidate for Mitomycin C, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

High-grade pseudomyxoma peritonei

3 optionsCompare side by side →

Cytoreductive surgery with HIPEC, with perioperative systemic chemotherapy (FOLFOX or CAPOX) as for appendiceal adenocarcinoma.

Guideline
NCCN Guidelines: Colon Cancer (appendiceal section)
The options, in plain words
HIPEC / PIPAC (intraperitoneal chemotherapy)Established

Washing the abdominal cavity with heated chemotherapy during surgery to kill microscopic peritoneal deposits.

  • High local concentration
FOLFOX (5-FU, leucovorin, oxaliplatin)Standard of careCytotoxic regimen

FOLFOX is the workhorse chemotherapy combination for bowel cancer, used after surgery to cure and in advanced disease as the backbone that targeted drugs are added to.

CAPOX (capecitabine, oxaliplatin)Standard of careCytotoxic regimen

CAPOX pairs the oral fluoropyrimidine capecitabine with intravenous oxaliplatin as a pill-based alternative to FOLFOX. For low-risk stage III colon cancer three months after surgery works as well as six and halves nerve damage; it is also standard in gastric cancer, with hand-foot syndrome as its price.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
HIPEC / PIPAC (intraperitoneal chemotherapy)
  • Morbidity, centre expertise
  • Mixed trial results
Questions to ask about this decision
  1. Between HIPEC / PIPAC (intraperitoneal chemotherapy), FOLFOX (5-FU, leucovorin, oxaliplatin) and CAPOX (capecitabine, oxaliplatin), which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Colon Cancer (appendiceal section)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (high-grade pseudomyxoma peritonei), which of the standard options do you recommend and why?
    Why: Guideline options include: Cytoreductive surgery with HIPEC, with perioperative systemic chemotherapy (FOLFOX or CAPOX) as for appendiceal adenocarcinoma.
  6. Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), CAPOX (capecitabine, oxaliplatin), and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Second line

Unresectable or recurrent disease

2 options

Repeat cytoreduction where feasible; debulking for symptoms; systemic chemotherapy only for high-grade histology; trials of mucolytics and pressurised intraperitoneal aerosol chemotherapy.

Guideline
NCCN Guidelines: Colon Cancer (appendiceal section)
The options, in plain words
HIPEC perfusion pumps and PIPAC nebulisersEstablished

The pump and heater that circulate warm chemotherapy through the abdomen at the end of an operation for cancer that has spread across the abdominal lining, and the small nebuliser that sprays chemotherapy as an aerosol through keyhole ports when surgery is not possible.

  • Direct exposure of the peritoneal surface at high concentration
  • Heat enhances platinum and mitomycin cytotoxicity
  • PIPAC is repeatable and low-dose
FOLFOX (5-FU, leucovorin, oxaliplatin)Standard of careCytotoxic regimen

FOLFOX is the workhorse chemotherapy combination for bowel cancer, used after surgery to cure and in advanced disease as the backbone that targeted drugs are added to.

Also referenced:Debulking (cytoreductive surgery)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
HIPEC perfusion pumps and PIPAC nebulisers
  • Benefit depends on complete cytoreduction
  • Randomised evidence mixed by tumour type
  • Specialist centres only; staff drug exposure needs controls
Questions to ask about this decision
  1. Between HIPEC perfusion pumps and PIPAC nebulisers and FOLFOX (5-FU, leucovorin, oxaliplatin), which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Colon Cancer (appendiceal section)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (unresectable or recurrent disease), which of the standard options do you recommend and why?
    Why: Guideline options include: Repeat cytoreduction where feasible; debulking for symptoms; systemic chemotherapy only for high-grade histology; trials of mucolytics and pressurised intraperitoneal aerosol chemotherapy.
  6. Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.